title: Cisplatin, doxorubicin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma.
abstract: A total of 43 patients with non-small cell carcinoma from a small preliminary trial and a larger in-house study were evaluated after treatment with cisplatin (50 mg/m2), doxorubicin (50 mg/m2), cyclophosphamide (300 mg/m2), and vincristine (1.4 mg/m2), all given iv on Day 1, and lomustine (50 mg/m2) given orally on Day 1. The response rate in the larger trial was 9%, with a 95% confidence interval of 2%-24%. For the combined group of all patients, median survival was 200 days, with a 95% confidence interval of 115-229 days. Hematologic toxicity and nausea and vomiting were moderate to severe and there were two treatment-related deaths. This combination drug regimen appears to have no advantages over other, less toxic regimens in the treatment of non-small cell bronchogenic carcinoma.
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009325:Nausea / Q000139:chemically induced; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin